Multiple-cytokine-producing, mixed-cellularity, classical Hodgkin lymphoma with B symptoms and minimal-change nephrotic syndrome.
Nakayama-Ichiyama
Shoko
S
Yokote
Taiji
T
Kobayashi
Kichinosuke
K
Hirata
Yuji
Y
Akioka
Toshikazu
T
Hiraoka
Nobuya
N
Takayama
Ayami
A
Iwaki
Kazuki
K
Oka
Satoko
S
Takubo
Takayuki
T
Tsuji
Motomu
M
Hanafusa
Toshiaki
T
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D001761:Bleomycin / Q000008:administration & dosage; D002097:C-Reactive Protein / Q000032:analysis; D003606:Dacarbazine / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004487:Edema / Q000209:etiology; D005221:Fatigue / Q000209:etiology*; D005334:Fever / Q000209:etiology*; D006689:Hodgkin Disease / Q000097:blood / Q000150:complications* / Q000188:drug therapy / Q000473:pathology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D015850:Interleukin-6 / Q000097:blood / Q000378:metabolism*; D008297:Male; D009402:Nephrosis, Lipoid / Q000188:drug therapy / Q000209:etiology*; D010257:Paraneoplastic Syndromes / Q000188:drug therapy / Q000209:etiology*; D012008:Recurrence; D016539:Reed-Sternberg Cells / Q000737:chemistry* / Q000473:pathology; D013546:Sweating; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis / Q000378:metabolism*; D014747:Vinblastine / Q000008:administration & dosage
C508600:IL6 protein, human; D007166:Immunosuppressive Agents; D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha; D001761:Bleomycin; D014747:Vinblastine; D003606:Dacarbazine; D004317:Doxorubicin; D002097:C-Reactive Protein